{
    "organizations": [],
    "uuid": "e336d68651e24ad3ee2083a3efde544df4535c12",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-novartis-announces-nejm-publicatio/brief-novartis-announces-nejm-publication-of-updated-analysis-from-eliana-trial-showing-longer-term-durable-remissions-with-kymriah-in-children-young-adults-with-r-r-all-idUSFWN1PQ1G6",
    "ord_in_thread": 0,
    "title": "BRIEF-Novartis Announces NEJM Publication Of Updated Analysis From Eliana Trial Showing Longer-Term Durable Remissions With Kymriah In Children, Young Adults With R/R ALL",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 31 (Reuters) - Novartis AG:\n* NOVARTIS ANNOUNCES NEJM PUBLICATION OF UPDATED ANALYSIS FROM ELIANA TRIAL SHOWING LONGER-TERM DURABLE REMISSIONS WITH KYMRIAH™ IN CHILDREN, YOUNG ADULTS WITH R/R ALL\n* NOVARTIS AG - ‍IN ANALYSIS OF 75 INFUSED PATIENTS WITH 3 OR MORE MONTHS OF FOLLOW-UP, KYMRIAH DEMONSTRATED AN OVERALL REMISSION RATE OF 81%​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-01T06:20:00.000+02:00",
    "crawled": "2018-02-01T06:09:57.812+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "novartis",
        "ag",
        "novartis",
        "announces",
        "nejm",
        "publication",
        "updated",
        "analysis",
        "eliana",
        "trial",
        "showing",
        "durable",
        "remission",
        "child",
        "young",
        "adult",
        "novartis",
        "ag",
        "analysis",
        "infused",
        "patient",
        "month",
        "kymriah",
        "demonstrated",
        "overall",
        "remission",
        "rate",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}